BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) have earned a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and twelve have given a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $365.7857.

ONC has been the topic of a number of research analyst reports. Citigroup boosted their target price on BeOne Medicines from $399.00 to $405.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Truist Financial set a $400.00 price objective on BeOne Medicines in a research report on Monday, November 24th. Zacks Research lowered BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 28th. Citizens Jmp boosted their price target on shares of BeOne Medicines from $348.00 to $396.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Finally, Morgan Stanley increased their price target on shares of BeOne Medicines from $350.00 to $383.00 and gave the company an “overweight” rating in a research report on Monday, October 20th.

BeOne Medicines Trading Down 1.9%

Shares of ONC stock opened at $331.40 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.17 and a current ratio of 2.39. The company has a market capitalization of $39.28 billion, a price-to-earnings ratio of 649.80 and a beta of 0.45. BeOne Medicines has a 52-week low of $170.99 and a 52-week high of $385.22. The company has a 50-day simple moving average of $332.91 and a two-hundred day simple moving average of $301.64.

Insider Activity at BeOne Medicines

In related news, insider Lai Wang sold 5,000 shares of BeOne Medicines stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $350.06, for a total value of $1,750,300.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Chan Henry Lee sold 996 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $349.17, for a total value of $347,773.32. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 81,094 shares of company stock worth $27,929,161 over the last 90 days. Corporate insiders own 6.62% of the company’s stock.

Institutional Investors Weigh In On BeOne Medicines

Large investors have recently added to or reduced their stakes in the company. Primecap Management Co. CA purchased a new stake in BeOne Medicines during the second quarter valued at about $1,231,720,000. Capital International Investors lifted its stake in shares of BeOne Medicines by 3.3% during the 3rd quarter. Capital International Investors now owns 5,046,058 shares of the company’s stock valued at $1,716,883,000 after buying an additional 161,052 shares in the last quarter. Temasek Holdings Private Ltd bought a new position in BeOne Medicines in the 2nd quarter worth approximately $244,603,000. Marshall Wace LLP purchased a new position in BeOne Medicines in the 2nd quarter valued at approximately $113,190,000. Finally, Bank of America Corp DE raised its holdings in BeOne Medicines by 23.5% during the 3rd quarter. Bank of America Corp DE now owns 345,256 shares of the company’s stock valued at $117,629,000 after acquiring an additional 65,763 shares during the period. Hedge funds and other institutional investors own 48.55% of the company’s stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.